A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors

NCT03546894 · clinicaltrials.gov ↗

COMPLETED

Status

111

Enrollment

INDUSTRY

Sponsor class

Conditions

Anaplastic Lymphoma Kinase-positive
Carcinoma Non-small-cell Lung

Interventions

DRUG: Brigatinib
DRUG: Alectinib
DRUG: Ceritinib
DRUG: Lorlatinib
DRUG: Any FDA Approved ALK Inhibitors

Sponsor

Takeda